We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event

By LabMedica International staff writers
Posted on 21 Jun 2021
Print article
Image: LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event (Photo courtesy of LumiraDx)
Image: LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event (Photo courtesy of LumiraDx)
LumiraDx (London, UK) attended the virtual event of this year’s Medlab Middle East, the leading medical laboratory exhibition in the region for over 20 years. The event brought together over 23,000 medical laboratory, healthcare and trade professionals from more than 140 countries.

In 2021 Medlab Middle East was run as a hybrid event and once again co-locating with Arab Health, bringing together the healthcare and laboratory communities. This year’s online event allowed delegates to network with industry peers, meet virtually, explore the latest products and attend educational sessions. LumiraDx exhibited online for the first time at Medlab Middle East and introduced its transformational point of care solution, the innovative LumiraDx Platform which is designed to perform a broad menu of tests, including infectious disease, cardiovascular disease, diabetes, and coagulation disorders and deliver lab-comparable performance with results in less than 12 minutes. The next generation point of care diagnostic system combines a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.

LumiraDx also highlighted its COVID-19 testing solutions at MEDLAB Middle East 2021, including its recently launched SARS-CoV-2 Antigen Test for use on the LumiraDx Platform which delivers results in 12 minutes with 97.6% PPA to an EUA approved RT-PCR method within the first 12 days of symptom onset. The use of a LumiraDx SARS-CoV-2 Ag Test on the LumiraDx Instrument enables the physician to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection. Also on display was the LumiraDx SARS-CoV-2 Ag Pool Test, a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to five individuals suspected of COVID-19 or up to five asymptomatic individuals. Used with the LumiraDx Platform, the test offers a rapid, scalable and cost-effective screening solution for infectious individuals. The company also showcased the LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform, the test delivers rapid results at the point of care.

Related Links:
LumiraDx

New
Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg
New
PLGF ELISA Kit
Placental Growth Factor ELISA
New
Automated Nucleic Acid Extraction System
GenoXtract fleXT
New
Gold Supplier
Bartonella Immunofluorescence Assay
BARTONELLA IFA

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.